More Than 40% of Prostate Biopsies Could Be Avoided with a New Blood Test

A new blood test called IsoPSA could prevent more than 40% of prostate biopsies, according to a study presented at the 13th American Urological Association Annual Meeting.
IsoPSA is used to distinguish high-grade (Gleason score ≥ 7) prostate cancer from benign (noncancerous) conditions or low-grade (Gleason = 6) prostate cancer, and is a protein biomarker.
The results showed that IsoPSA measurement, both in the preliminary study (45%) and validation study (47%), could prevent more than 40% of prostate biopsies. Thus, IsoPSA may substantially reduce the need for prostate biopsies and, consequently, overdiagnosis and overtreatment of nonaggressive prostate cancer (unlikely to cause death).
Cleveland Clinic researcher Dr. Eric Klein and his team’s preliminary study was confirmed by a multicenter validation study. This also clarified the cutoff parameters (normal and above-normal values) of the IsoPSA tumor marker.
To be clinically useful, a biomarker must be both tissue-specific and cancer-specific. Conventional prostate- specific antigen (PSA) is specific to the prostate but not to prostate cancer; PSA may also rise in many other diseases affecting the prostate. This leads to diagnostic errors and many unnecessary biopsies. IsoPSA meets the tissue and cancer specificity required of a useful biomarker. This validation study shows that it can detect high-grade prostate cancer more accurately and reduce unnecessary biopsies in patients at low risk of the disease. With larger clinical trials in the coming period, IsoPSA measurement may enter routine practice.
Sources
Prospective Validation of The IsoPSA Assay for Detection of High Grade Prostate Cancer.
13th Annual Meeting of the American Urological Association (AUA) (Abstract PD60-05).
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.